# Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A

> **NCT01454739** · PHASE3 · COMPLETED · sponsor: **Bioverativ Therapeutics Inc.** · enrollment: 240 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **DRUG:** rFVIIIFc

## Key facts

- **NCT ID:** NCT01454739
- **Lead sponsor:** Bioverativ Therapeutics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2020-12-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01454739

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01454739, "Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT01454739. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*